12P - Volatolomic signatures of anaplastic lymphoma kinase gene rearrangement in adenocarcinoma

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Thoracic Malignancies
Pathology/Molecular Biology
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter TOYOAKI Hida
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors T. Hida1, Y. Oya1, K. Tanaka2, T. Yoshida2, J. Shimizu2, Y. Horio2, Y. Yatabe3, T. Itoh4, W. Shin4
  • 1Thoracic Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 2Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya/JP
  • 3Pathology And Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya/JP
  • 4Materials And Chemistry, National Institute of Advanced Industrial Science and Technology, Nagoya/JP



The search for non-invasive diagnostic methods of lung cancer has led to new avenues of research, including the exploration of the exhaled breath. The collection and analysis of exhaled volatile organic compounds (VOCs) is non-invasive and could be easily applied in the broad range of patients. Epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) gene rearrangement are present among lung adenocarcinoma, with the implication that patients with these genotypes were super responders to EGFR-tyrosine kinase inhibitors (TKIs) or ALK-TKIs. In this study, we analyzed exhaled VOCs of the patients with adenocarcinoma in order to identify useful information regarding patient selection for gene mutations.


Patients with adenocarcinoma (63 mutation negative, 29 EGFR mutation, 8 KRAS mutation, 6 ALK gene rearrangement) participated. All the subjects had biopsy-proven, untreated adenocarcinoma. Subjects were asked to perform a single slow vital capacity breath in a oneway 1L Analytic- Barrier™ bag, which traps the last portion of exhaled breath (alveolar breath). Profiles of VOCs were determined by gas chromatography/mass spectrometry (Shimadzu Co. Ltd.). Written informed consent was obtained from all subjects.


Among 58 VOCs detected and identified in the GC/MS analysis, we identified 4 VOCs significantly different between adenocarcinoma with ALK gene rearrangement and other adenocarcinomas. Four VOCs were significantly lower concentrations in patients with ALK gene rearrangement. Now, exhaled breath air monitoring system (sensors as detector) for lung cancer-related VOCs is under development.


Our data suggest that compounds in breath could possibly be taken as useful breath biomarkers, and analysis of specific VOC may differentiate ALK positive lung adenocarcinoma from other lung adenocarcinoma, although further conclusive studies that involve a larger cohort should be performed.

Clinical trial identification

Legal entity responsible for the study

Toyoaki Hida


Knowledge Hub Aichi


All authors have declared no conflicts of interest.